TY - JOUR
T1 - Drug discovery in paediatric oncology
T2 - Roadblocks to progress
AU - Adamson, Peter C.
AU - Houghton, Peter J.
AU - Perilongo, Giorgio
AU - Pritchard-Jones, Kathy
N1 - Funding Information:
P.J.H. is supported by grants CA77776, CA165995 and NO1-CM-42216 from the National Cancer Institute. G.P. thanks Francois Doz and Gabriele Calaminus for useful discussions. K.P.-J. is supported by the UK National Institute for Health Research Great Ormond Street Hospital University College London Biomedical Research Centre award and the European Union’s Seventh Framework Programme (FP7/2007–13) under the European Network for Cancer Research in Children and Adolescents project (grant number 261474).
Publisher Copyright:
© 2014 Macmillan Publishers Limited. All rights reserved.
PY - 2014/12/11
Y1 - 2014/12/11
N2 - Approval of new cancer drugs for paediatric patients generally occurs after their development and approval for treating adult cancers. As most drug development occurs in the industry setting, the relatively small market of paediatric oncology does not provide the financial incentives for companies to actively pursue paediatric oncology solutions. Indeed, between 1948 and January 2003 the FDA approved 120 new cancer drugs, of which only 30 have been used in children. This slow rate of development must be addressed in a meaningful way if we are to make progress in the most pressing settings in childhood cancer. In this Viewpoint article, the key opinion leaders in the field weigh in and offer practical advice on how to address this issue.
AB - Approval of new cancer drugs for paediatric patients generally occurs after their development and approval for treating adult cancers. As most drug development occurs in the industry setting, the relatively small market of paediatric oncology does not provide the financial incentives for companies to actively pursue paediatric oncology solutions. Indeed, between 1948 and January 2003 the FDA approved 120 new cancer drugs, of which only 30 have been used in children. This slow rate of development must be addressed in a meaningful way if we are to make progress in the most pressing settings in childhood cancer. In this Viewpoint article, the key opinion leaders in the field weigh in and offer practical advice on how to address this issue.
UR - http://www.scopus.com/inward/record.url?scp=84927177504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927177504&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2014.149
DO - 10.1038/nrclinonc.2014.149
M3 - Review article
C2 - 25223555
AN - SCOPUS:84927177504
SN - 1759-4774
VL - 11
SP - 732
EP - 739
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 12
ER -